دورية أكاديمية
أعرض في EDS

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.

التفاصيل البيبلوغرافية
العنوان: An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
المؤلفون: Scherer SD; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Riggio AI; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Haroun F; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., DeRose YS; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Ekiz HA; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Fujita M; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Toner J; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Zhao L; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA., Li Z; Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Magee Women's Research Institute, University of Pittsburgh, 204 Craft Avenue, Pittsburgh, PA, 15213, USA., Oesterreich S; Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Magee Women's Research Institute, University of Pittsburgh, 204 Craft Avenue, Pittsburgh, PA, 15213, USA., Samatar AA; Zentalis Pharmaceuticals, Inc., 10835 Road to the Cure, Suite 205, San Diego, CA, 92121, USA., Welm AL; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA. alana.welm@hci.utah.edu.; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA. alana.welm@hci.utah.edu.
المصدر: Breast cancer research : BCR [Breast Cancer Res] 2021 Oct 30; Vol. 23 (1), pp. 100. Date of Electronic Publication: 2021 Oct 30.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Publication: London, UK : BioMed Central Ltd
Original Publication: London, UK : Current Science, c1999-
مواضيع طبية MeSH: Drug Resistance, Neoplasm*/genetics, Breast Neoplasms/*immunology , Breast Neoplasms/*pathology , Receptors, Estrogen/*metabolism , Xenograft Model Antitumor Assays/*methods, Animals ; Antigens, CD34/metabolism ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Disease Models, Animal ; Estrogen Receptor alpha/genetics ; Estrogens/administration & dosage ; Estrogens/pharmacology ; Female ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells/metabolism ; Heterografts/drug effects ; Heterografts/metabolism ; Heterografts/pathology ; Humans ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Mice, Transgenic ; Mutation ; Receptors, Estrogen/genetics ; Tumor Microenvironment/immunology
مستخلص: Background: Metastatic breast cancer (MBC) is incurable, with a 5-year survival rate of 28%. In the USA, more than 42,000 patients die from MBC every year. The most common type of breast cancer is estrogen receptor-positive (ER+), and more patients die from ER+ breast cancer than from any other subtype. ER+ tumors can be successfully treated with hormone therapy, but many tumors acquire endocrine resistance, at which point treatment options are limited. There is an urgent need for model systems that better represent human ER+ MBC in vivo, where tumors can metastasize. Patient-derived xenografts (PDX) made from MBC spontaneously metastasize, but the immunodeficient host is a caveat, given the known role of the immune system in tumor progression and response to therapy. Thus, we attempted to develop an immune-humanized PDX model of ER+ MBC.
Methods: NSG-SGM3 mice were immune-humanized with CD34+ hematopoietic stem cells, followed by engraftment of human ER+ endocrine resistant MBC tumor fragments. Strategies for exogenous estrogen supplementation were compared, and immune-humanization in blood, bone marrow, spleen, and tumors was assessed by flow cytometry and tissue immunostaining. Characterization of the new model includes assessment of the human tumor microenvironment performed by immunostaining.
Results: We describe the development of an immune-humanized PDX model of estrogen-independent endocrine resistant ER+ MBC. Importantly, our model harbors a naturally occurring ESR1 mutation, and immune-humanization recapitulates the lymphocyte-excluded and myeloid-rich tumor microenvironment of human ER+ breast tumors.
Conclusion: This model sets the stage for development of other clinically relevant models of human breast cancer and should allow future studies on mechanisms of endocrine resistance and tumor-immune interactions in an immune-humanized in vivo setting.
(© 2021. The Author(s).)
References: Nat Genet. 2021 Jan;53(1):86-99. (PMID: 33414553)
J Clin Oncol. 2007 Nov 20;25(33):5287-312. (PMID: 17954709)
Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188. (PMID: 29104025)
Front Immunol. 2019 Jun 06;10:1307. (PMID: 31244851)
J Immunother Cancer. 2017 Jul 18;5(1):53. (PMID: 28716061)
Cell Mol Immunol. 2012 May;9(3):215-24. (PMID: 22425741)
Can Vet J. 2009 Oct;50(10):1054-8. (PMID: 20046604)
J Am Assoc Lab Anim Sci. 2009 Jan;48(1):11-22. (PMID: 19245745)
Nat Rev Cancer. 2017 Apr;17(4):254-268. (PMID: 28104906)
Front Oncol. 2020 Jun 09;10:899. (PMID: 32656079)
Br J Cancer. 2019 Jan;120(1):45-53. (PMID: 30413828)
Leukemia. 2004 Feb;18(2):341-7. (PMID: 14628073)
Nat Med. 2011 Oct 23;17(11):1514-20. (PMID: 22019887)
Nat Rev Immunol. 2012 Nov;12(11):786-98. (PMID: 23059428)
Cancer Res. 2013 Aug 1;73(15):4885-97. (PMID: 23737486)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32217760)
Immunotherapy. 2019 Feb;11(3):201-213. (PMID: 30730277)
Am J Cancer Res. 2019 Dec 01;9(12):2821-2831. (PMID: 31911865)
Nat Biotechnol. 2014 Apr;32(4):364-72. (PMID: 24633240)
Oncotarget. 2012 Dec;3(12):1497-8. (PMID: 23455077)
Cell Immunol. 2019 Sep;343:103713. (PMID: 29129292)
Nat Med. 2013 Nov;19(11):1423-37. (PMID: 24202395)
Cell. 2017 Sep 7;170(6):1055-1056. (PMID: 28886376)
J Am Vet Med Assoc. 1981 Jun 15;178(12):1293-4. (PMID: 7196908)
Clin Cancer Res. 2016 Mar 1;22(5):1130-7. (PMID: 26500237)
J Clin Immunol. 2011 Apr;31(2):253-64. (PMID: 20981478)
Cancer Res. 2014 Mar 1;74(5):1463-74. (PMID: 24425047)
Endocr Relat Cancer. 2018 May;25(5):R319-R330. (PMID: 29563191)
NPJ Breast Cancer. 2019 Oct 29;5:37. (PMID: 31700993)
Nat Cancer. 2021 Jan;2(1):66-82. (PMID: 33738458)
EMBO Mol Med. 2020 Jul 7;12(7):e8662. (PMID: 32578942)
Haematologica. 2006 Oct;91(10):1384. (PMID: 17018389)
Semin Cancer Biol. 2008 Oct;18(5):349-55. (PMID: 18467122)
Blood. 2011 Mar 17;117(11):3076-86. (PMID: 21252091)
J Immunol. 2014 May 15;192(10):4636-47. (PMID: 24740501)
Curr Protoc Pharmacol. 2020 Jun;89(1):e77. (PMID: 32453514)
Br J Cancer. 2021 Jan;124(1):191-206. (PMID: 33257837)
Sci Rep. 2017 Dec 4;7(1):16878. (PMID: 29203879)
J Exp Clin Cancer Res. 2021 Jan 7;40(1):19. (PMID: 33413549)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
J Immunother Cancer. 2019 Feb 8;7(1):37. (PMID: 30736857)
Horm Cancer. 2017 Feb;8(1):4-15. (PMID: 27796944)
Cancer Cell. 2018 Feb 12;33(2):173-186.e5. (PMID: 29438694)
Oncogene. 2017 Apr 20;36(16):2286-2296. (PMID: 27748765)
Nat Rev Immunol. 2015 Feb;15(2):73-86. (PMID: 25614318)
Nat Commun. 2022 Apr 19;13(1):2011. (PMID: 35440136)
Nat Cancer. 2022 Feb;3(2):232-250. (PMID: 35221336)
Nature. 2015 Feb 19;518(7539):422-6. (PMID: 25470049)
J Immunol. 2013 Mar 1;190(5):2090-101. (PMID: 23335750)
Immunity. 2018 Apr 17;48(4):812-830.e14. (PMID: 29628290)
Elife. 2016 Feb 02;5:. (PMID: 26836308)
Cancer Res. 1997 Apr 1;57(7):1244-9. (PMID: 9102207)
Breast Cancer Res. 2018 Sep 5;20(1):108. (PMID: 30185216)
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226)
Breast Cancer Res. 2020 Jun 23;22(1):68. (PMID: 32576280)
Cancer Metastasis Rev. 2016 Dec;35(4):547-573. (PMID: 28025748)
Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23. (PMID: 23456611)
Cell. 2017 Sep 7;170(6):1109-1119.e10. (PMID: 28886381)
Cell. 2018 Aug 9;174(4):1031-1032. (PMID: 30096300)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33239416)
J Vis Exp. 2016 Apr 14;(110):. (PMID: 27168390)
Cancer Immunol Res. 2019 Aug;7(8):1267-1279. (PMID: 31186248)
Cell Immunol. 2015 Apr;294(2):63-9. (PMID: 25682174)
Blood. 2010 Nov 18;116(20):4158-67. (PMID: 20671122)
Cancer Metastasis Rev. 2010 Jun;29(2):309-16. (PMID: 20405169)
Front Immunol. 2020 Sep 02;11:1842. (PMID: 32983100)
Cancers (Basel). 2019 Feb 06;11(2):. (PMID: 30736340)
Clin Cancer Res. 2020 Oct 1;26(19):5172-5177. (PMID: 32546646)
Trends Cancer. 2020 Jul;6(7):605-618. (PMID: 32610070)
Endocr Relat Cancer. 2016 Nov;23(11):C9-C12. (PMID: 27619257)
Front Immunol. 2019 Feb 13;10:186. (PMID: 30814997)
Nat Rev Cancer. 2017 May;17(5):302-317. (PMID: 28303905)
Cancer Res. 2021 Feb 1;81(3):539-551. (PMID: 33184109)
Cells. 2020 Jul 27;9(8):. (PMID: 32726950)
Front Immunol. 2020 Sep 08;11:2082. (PMID: 33013879)
FASEB J. 2018 Mar;32(3):1537-1549. (PMID: 29146734)
Front Immunol. 2020 May 15;11:940. (PMID: 32499786)
معلومات مُعتمدة: UL1 TR002538 United States TR NCATS NIH HHS; 5P30CA042014 United States CA NCI NIH HHS; R01 CA221303 United States CA NCI NIH HHS; UL1TR002538 United States NH NIH HHS; P30 CA042014 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Breast cancer tumor microenvironment; ER+ PDX; ER+ metastatic breast cancer; ESR1 mutation; Endocrine resistance model; Estrogen supplementation; Humanized PDX; Immune-humanization; Y537S
المشرفين على المادة: 0 (Antigens, CD34)
0 (ESR1 protein, human)
0 (Estrogen Receptor alpha)
0 (Estrogens)
0 (Receptors, Estrogen)
تواريخ الأحداث: Date Created: 20211031 Date Completed: 20220301 Latest Revision: 20240404
رمز التحديث: 20240404
مُعرف محوري في PubMed: PMC8556932
DOI: 10.1186/s13058-021-01476-x
PMID: 34717714
قاعدة البيانات: MEDLINE
الوصف
تدمد:1465-542X
DOI:10.1186/s13058-021-01476-x